Alltrna

United States - Cambridge, Massachusetts

• 09/08/2023
• Series B
• $109,000,000

Alltrna is the first transfer RNA (tRNA) platform company, and our mission is to unlock tRNA biology and pioneer tRNA therapeutics to regulate the protein universe and resolve disease. Founded at Flagship Labs in 2018, Alltrna has mapped tRNA biology to systematically design tRNA medicines and encode a completely new, unifying approach to treating both rare and common human diseases driven by shared genetic mutations. Alltrna’s platform combines internal expertise and proprietary machine learning tools to unlock the entire tRNA biology space. We have an unprecedented opportunity to advance a single tRNA medicine to restore disrupted protein production, regardless of target, for thousands of diseases with the same underlying genetic mutation.

Related People

Lovisa AfzeliusFounder

United States - Belmont, Massachusetts

Lovisa Afzelius is an origination partner at Flagship Pioneering. Lovisa has held or holds leadership positions such as CEO, co-founder, president, chairman of the board, and executive director across emerging biotech companies as well as large pharma. A computational scientist by training, she brings two decades of leadership experience and a passion for data-driven drug discovery, from early inception to clinical development across multiple therapeutic areas. Business delivery oriented, ambitious and highly motivated individual with excellent track-record of developing and executing complex strategic and operational plans across boundaries in a global matrix organization.

LinkedIn https://www.linkedin.com/in/lovisa-afzelius-9823628/